University of Kentucky Research Foundation

Memorial Sloan Kettering Cancer Center

St. Jude Children's Research Hospital

Rutgers, the State University of New Jersey

Cal Poly Corporation

Jared T Hammill

Daniel C Scott

Bhuvanesh Singh

Jaeki Min

R Kiplin Guy

Brenda A Schulman

Deepak Bhasin

Rodney Kiplin Guy

Peter Anthony Crooks

Stefan Kwiatkowski

Linda P Dwoskin

Jon Scott Thorson

Guangrong Zheng

David S Watt

Spencer Knapp

Robert D Barrows

Mark Leggas

Na-Ra Lee

Derong Ding

Hoshin Kim

Kip Guy

Christopher Davis

Scott Charles Eagon

Brenda Arlene Schulman

A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Pharmaceutically active pyrazolo-pyridone modulators of DCN1/2-mediated cullin neddylation

Disclosed are methods of treating malaria with tetrahydrobenzonaphtyridine carboxanilide (TBN) derivatives and related pyrrolinones and hydrolysis products thereof. These compounds are active againststrains that are resistant to multiple drugs currently on the market. The present invention further relates to novel compounds and pharmaceutical compositions comprising such compounds.

Compositions and methods for treating malaria

The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse

In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods and compositions of inhibiting DCN1-UBC12 interaction

The present invention relates to pyrazolo[3,4-b]pyridine compounds. The present invention further relates to methods for inhibitingcomprising contactingwith pyrazolo[3,4-b]pyridine compounds described herein. Also described herein are methods of treating malaria comprising administering pyrazolo[3,4-b]pyridine compounds to a subject in need thereof.

Preparation of pyrazolo[3,4-B]pyridines as antimalarials

Growing community of inventors

Lexington, KY, United States of America

Jared T Hammill